TICKERNERD
Menu
RKDARKDAConsumer Defensive · Packaged Foods

RKDA Stock Forecast: Arcadia Biosciences, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.43
−4.83% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 11 Sept 2026 — in the lower half.

Market cap
$1.0M
Ticker Nerd rank
33 / 100
Median analyst target
—
Analysts covering
1
Revenue$1.4M−0.8% y/y
Operating income−$496K
Net income−$6.3M
Free cash flow−$319K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.7%
1M
−35.7%
YTD
−78.2%
1Y
−87.6%
From 52W high
−92.1%
From 52W low
+2.4%
$0.42
$5.48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RKDA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcadia Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
100
Accruals
99
Growth
87
Issuance
35
Revisions
25
Momentum
24
Quality
15
Volatility
13
Value
2

Size (100): Smaller than most of the companies we track.

Value (2): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RKDA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RKDA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26RKDA

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Recent analyst actionsNewest first

Of the 19 most recent actions, 1 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
21 Aug 2024HC Wainwright & Co.ReiteratesBuy$6.00
21 Aug 2024HC Wainwright & Co.ReiteratesBuy—
23 May 2024HC Wainwright & Co.MaintainsBuy—
5 Apr 2024HC Wainwright & Co.ReiteratesBuy—
28 Aug 2023HC Wainwright & Co.MaintainsBuy—
24 July 2023HC Wainwright & Co.ReiteratesBuy—
5 June 2023HC Wainwright & Co.MaintainsBuy—
14 Apr 2023HC Wainwright & Co.MaintainsBuy—
26 Aug 2022HC Wainwright & Co.MaintainsBuy$4.00 → $3.00
3 Jan 2022HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
1 June 2021HC Wainwright & Co.MaintainsBuy$6.00 → $7.00
11 May 2021Lake StreetInitiatesBuy—
9 Feb 2021HC Wainwright & Co.MaintainsBuy$8.00 → $6.00
30 Nov 2020HC Wainwright & Co.MaintainsBuy$12 → $10
17 Aug 2020HC Wainwright & Co.MaintainsBuy$14 → $12
20 June 2018H.C. WainwrightInitiatesBuy—
19 June 2018H.C. WainwrightInitiatesBuy—
12 May 2017PiperJaffrayDowngradeNeutral—
9 June 2015Credit SuisseInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RKDA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RKDA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Arcadia Biosciences, Inc. returned −87.6% against +17.5% for the S&P 500, dividends included.

RKDA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26RKDAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RKDA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Arcadia Biosciences, Inc. (RKDA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.3×

Cheaper than 78% of US stocks

Price / sales
0.2×

Cheaper than 91% of US stocks

Price / book
1.5×

Cheaper than 52% of US stocks

EV / EBITDA
0.8×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
−0.8%

Higher than 26% of US stocks

Earnings growth (YoY)
−0.8%

Higher than 35% of US stocks

Gross margin
43.7%

Higher than 54% of US stocks

Operating margin
−34.4%

Higher than 19% of US stocks

Net margin
−234.5%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−430.9%

Higher than 4% of US stocks

Return on assets
−34.8%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arcadia Biosciences, Inc. (RKDA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arcadia Biosciences, Inc. has a market value of $1.0M and an enterprise value of −$3.1M.

  • Revenue in the twelve months to 30 June 2026: $4.7M. The latest quarter shrank 0.8% year on year.

  • Net income over the same four quarters: −$11.1M, a −234.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.5M.

  • Shares outstanding: 2.2M.

  • Trailing P/E: −0.3×; forward P/E: −0.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arcadia Biosciences, Inc. employs 8 people — $593K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

RKDA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
RKDAArcadia Biosciences, Inc.$1.0M
33
ATPCAgape ATP Corp.$2.4M
42
PAVSParanovus Entertainment Technology Ltd.$3.9M
33
FAMIFarmmi, Inc.$4.6M
20
NCRANocera, Inc.$5.3M
13
NAIINatural Alternatives International, Inc.$12.1M
38
DDCDDC Enterprise Ltd.$14.8M
4

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arcadia Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RKDA news & analysis

Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

GlobeNewsWire · 13 Aug 2026positive

Arcadia Biosciences released its financial and business results for the second quarter and first half of 2026. The company reported net cash used in operating activities of only $319K in the quarter, closed a $4 million private placement, and ended the quarter with $4.2 million in cash, while July Zola sales topped $740K and surpassed $1 million through the first week of August.

Why it matters — The results highlight improved cash usage, a strengthened cash position from a private placement, and rising Zola sales, which are key indicators of Arcadia's operating performance and financial runway.

FAQ

Frequently asked questions about RKDA stock

Is RKDA stock a buy right now?

Of the 1 analysts covering Arcadia Biosciences, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcadia Biosciences, Inc. 33 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RKDA?

As at 11 Sept 2026, Arcadia Biosciences, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).

What is the RKDA stock forecast for 2030?

No analyst covering Arcadia Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RKDA are extrapolating price history, which says nothing about the business.

How has RKDA stock performed over the past year?

Arcadia Biosciences, Inc. returned -87.6% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcadia Biosciences, Inc. do?

Arcadia Biosciences Inc. is a biotechnology company focused on plant-based products and agricultural innovations.

What is the latest news on RKDA?

The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights". Arcadia Biosciences released its financial and business results for the second quarter and first half of 2026. The company reported net cash used in operating activities of only $319K in the quarter, closed a $4 million private placement, and ended the quarter with $4.2 million in cash, while July Zola sales topped $740K and surpassed $1 million through the first week of August.

Company

About Arcadia Biosciences, Inc.

Arcadia Biosciences Inc. is a biotechnology company focused on plant-based products and agricultural innovations. The company develops and markets specialty crop ingredients, including wheat-based food ingredients designed to improve nutrition and functionality for food manufacturers and processors. Its portfolio also includes consumer products such as Zola coconut water and wellness offerings, reflecting its presence across food, beverage, and health-oriented product categories. Arcadia Biosciences works with crop traits and ingredient platforms that serve growers, ingredient buyers, and consumer brands, positioning the company at the intersection of agricultural science and packaged goods. Headquartered in Dallas, Texas, Arcadia Biosciences Inc. concentrates on current products and commercial offerings in the plant-based nutrition and wellness market.

CEO Mr. Thomas J. Schaefer C.F.A. · 8 employees · United States · https://arcadiabio.com